** Shares of drug developer Tevogen Bio closed up about 5% at $1.80
** Company forecasts top line revenue for its specialty care pipeline to be nearly $1 bln in its launch year
** Cumulative 5-year revenue estimate between $18 bln and $22 bln - TVGN
** Company's pipeline includes treatment for Covid-19 infection in patients with certain cancers, as well as arthritis
** Up to last close, stock was down 84.2% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。